Selective ROCK2Inhibition forCardiovascularDiseases

Science

Why ROCK2

Rho associated protein kinase 2 (ROCK2) is a serine/threonine protein kinase that helps regulate fibrosis, inflammation, vascular remodeling and central nervous system maturation. These processes are central to how blood vessels and the heart respond to stress and participate in the pathogenesis of multiple cardiac disease processes.

Cell behavior

ROCK2 is a downstream target of RhoA and mediates myosin light chain phosphorylation, processes that are key to smooth muscle cell proliferation, fibroblast activation and vascular remodeling.

Selectivity

ROCK2 selectivity is key to avoiding some of the counter effects of ROCK1 inhibition and to avoiding some of the side effects of pan-ROCK inhibitors.

Cardiovascular focus

In cardiac tissue and pulmonary vasculature, there is greater expression of ROCK 2 vs ROCK1. The pathologic effects of ROCK 2 activation are most important for cardiopulmonary indications such as pulmonary arterial hypertension, heart failure with preserved ejection fraction, and additional cardiomyopathies.

Mechanism

ROCK2 Inhibition in Pulmonary Hypertension, Heart Failure with Preserved Ejection Fraction (HFpEF) and Cardiomyopathies

Antifibrotic

In the heart, fibroblast-specific ROCK2 inhibition has been shown to reduce fibrosis and improve diastolic dysfunction. In the lung and pulmonary vasculature, ROCK inhibition decreased collagen deposition and fibrosis. ROCK2 signaling links TGF-β and mechanical stress to fibroblast activation, actin remodeling, and extracellular matrix production. Inhibiting ROCK2 can reduce myofibroblast differentiation, CTGF (Connective Tissue Growth Factor) expression, and collagen deposition.

Anti-inflammatory

ROCK2 inhibition has been shown to decrease inflammatory-cell recruitment and cytokine release, potentially reducing immune-driven activation of cardiac and pulmonary fibroblasts. ROCK2 regulates immune-cell activity through pathways including STAT3 and STAT5, which help set the balance between inflammatory and regulatory T-cell responses. Selective ROCK2 inhibition also reduces the production of IL-17 and IL-21, two key pro-inflammatory cytokines.

Anti-hypertrophy

ROCK2 drives pathological cardiac growth through cardiomyocyte signaling and fibroblast-derived growth factors. In pulmonary vessels, ROCK2 inhibition suppresses smooth-muscle proliferation and remodeling. Antagonizing ROCK2 in cardiomyocytes increased FHL2-associated restraint of SRF/ERK signaling and reduced hypertrophy after angiotensin II exposure or pressure overload.

At a Glance

Download PDF
Company
CinRock Pharma

Currently conducting multiple animal studies with selective ROCK2 Inhibitors in pulmonary hypertension, HFpEF and other cardiovascular diseases.

Founding Partners
CinRx Pharma and Graviton Bioscience
Target
ROCK2, Rho-associated coiled-coil kinase 2
Programs
Program 1: Pulmonary arterial hypertension (PAH)Program 2:Heart failure with preserved ejection fraction (HFpEF),
HCM